CN116497010A - G-7-adca合成酶及其在制备头孢烷酸类化合物中的应用 - Google Patents
G-7-adca合成酶及其在制备头孢烷酸类化合物中的应用 Download PDFInfo
- Publication number
- CN116497010A CN116497010A CN202210061179.6A CN202210061179A CN116497010A CN 116497010 A CN116497010 A CN 116497010A CN 202210061179 A CN202210061179 A CN 202210061179A CN 116497010 A CN116497010 A CN 116497010A
- Authority
- CN
- China
- Prior art keywords
- adca
- peng
- reaction
- synthase
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003960 Ligases Human genes 0.000 title claims abstract description 21
- 108090000364 Ligases Proteins 0.000 title claims abstract description 21
- YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical class S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Natural products N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 69
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 claims abstract description 11
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 108090000790 Enzymes Proteins 0.000 claims description 38
- 102000004190 Enzymes Human genes 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 10
- 210000001822 immobilized cell Anatomy 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 238000006555 catalytic reaction Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- -1 hnRNA Proteins 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003570 biosynthesizing effect Effects 0.000 claims 1
- 239000008394 flocculating agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 101710104123 Deacetoxycephalosporin C synthase Proteins 0.000 abstract description 12
- 238000006049 ring expansion reaction Methods 0.000 abstract description 7
- 230000003197 catalytic effect Effects 0.000 abstract description 5
- 238000011960 computer-aided design Methods 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract description 2
- 229940056360 penicillin g Drugs 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 12
- 239000004195 dipotassium inosinate Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000007036 catalytic synthesis reaction Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 6
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000228150 Penicillium chrysogenum Species 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 2
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010025076 Holoenzymes Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010073038 Penicillin Amidase Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- HOKIDJSKDBPKTQ-GLXFQSAKSA-N cephalosporin C Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 HOKIDJSKDBPKTQ-GLXFQSAKSA-N 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 150000001945 cysteines Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FCZNNHHXCFARDY-WQRUCBPWSA-N (2s,5r,6r)-3,3-dimethyl-4,7-dioxo-6-[(2-phenylacetyl)amino]-4$l^{4}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2=O)(C)C)C(O)=O)C(=O)CC1=CC=CC=C1 FCZNNHHXCFARDY-WQRUCBPWSA-N 0.000 description 1
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical group NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 101100136093 Penicillium crustosum penG gene Proteins 0.000 description 1
- 241000228417 Sarocladium strictum Species 0.000 description 1
- 241000187433 Streptomyces clavuligerus Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002742 combinatorial mutagenesis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 108010034416 glutarylamidocephalosporanic acid acylase Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011090 industrial biotechnology method and process Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003668 tyrosines Chemical group 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 150000003680 valines Chemical group 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01093—Glutaryl-7-aminocephalosporanic-acid acylase (3.5.1.93)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明通过计算机辅助设计获得一系列具有扩环活性的新型G‑7‑ADCA合成酶(突变体),并通过实验验证,获得提高了对PenG催化活性的G‑7‑ADCA合成酶。本发明的G‑7‑ADCA合成酶对于底物PenG具有比野生型扩环酶高出多倍的扩环酶活性,具有较大的应用价值。
Description
技术领域
本发明涉及生物技术领域,尤其涉及系列新的合成酶在合成G-7-ADCA中的应用。
背景技术
头孢菌素是β-内酰胺类抗生素的重要组成部分,具有耐药性高、对β-内酰胺酶稳定、毒副作用小等优点,对多种细菌、病毒感染具有良好疗效,在临床领域得到广泛应用。7-氨基-3-脱乙酰氧基头孢烷酸(7-ADCA)是重要的头孢菌素类抗生素合成母核,可用于合成头孢羟氨、头孢拉定、头孢克罗等药物,而G-7-ADCA又是合成7-ADCA的主要原料,市场需求量较大。
目前,以G-7-ADCA为中间体合成7-ADCA主要有三种方法:化学酶法、发酵法和全酶法。化学酶法制备7-ADCA以青霉素G(PenG)为原料,通过过氧乙酸将其氧化为青霉素G亚砜,然后扩环重排产生G-7-ADCA,最后在青霉素酰化酶的作用下脱去侧链生成7-ADCA。此工艺在实际生产中存在众多不足:①氧化过程所用的氧化剂为40%的过氧乙酸,成本高、危险性大、产生危害环境的酸性废水;②扩环反应所用的酯化剂BSU严重过量,导致生产成本高;③产品7-ADCA质量不稳定,影响7-ADCA的纯度及溶解度,从而影响产品的纯度。
在CN1075336A中公开,通过发酵法制备7-ADCA,将来源于StreptomycesClavuligerus菌株扩环酶(scDAOCS)基因导入到产黄青霉菌(Penicilliumchrysogenum)中,在发酵培养基中添加己二酸,产黄青霉菌利用己二酸产生己二酰-6-APA,进一步通过产黄青霉菌扩环酶,将己二酰-6-APA环扩为己二酰-7-ADCA,然后利用己二酰酰基转移酶裂解己二酰侧链而获得终产物7-ADCA。Alvarez等(Antimicrobial Agents&Chemotherapy,1987,31(11):1675-82)发现在顶头孢霉菌中,以脱乙酰氧头孢菌素C(DAOC)为底物,在D型氨基酸氧化酶(DAO)催化下转化为酮己二酸-7-ADCA,同时产生过氧化氢,进一步通过过氧化氢的氧化生成戊二酰-7-ADCA(GL-7-ADCA),最后在戊二酰酰化酶催化下生成7-ADCA。由此可见,发酵法合成G-7-ADCA工艺步骤多并且存在发酵周期长等问题。
全酶法制备7-ADCA,以PenG为底物在扩环酶作用下扩环合成G-7-ADCA,G-7-ADCA在青霉素酰化酶的催化下发生水解反应合成7-ADCA,其合成路线如图1所示。该过程环保且工艺步骤简单,但扩环酶酶活较低,无法应用到工业生产中。因此,为了提高扩环酶的酶活性,进行了理性和非理性的改造。Hsu等(Applied and Environmental Microbiology,2004,70(10):6257-6263)将8个不同菌属来源的基因进行DNA shuffling,获取FF8突变体,针对底物PenG的活性(kcat/KM)增加了117.8倍,但未测定对PenG的转化率。Ji等(Appliedand Environmental Microbiology,2012,78(21):7809-7812)在前人基础上,通过迭代组合突变,获得C155Y/Y184H/V275I/C281Y/I305M/S261M、C155Y/Y184H/V275I/C281Y/I305M/T213V/M73T以及C155Y/Y184H/V275I/C281Y/I305M/T213V/S261M等组合突变体,活性提高了7-8倍,是目前报道活性最高的突变体。CN1446908A中描述了一种扩环酶,在该专利文献中,提到了将155位半胱氨酸替换为酪氨酸、184位酪氨酸替换为组氨酸、275位缬氨酸替换为异亮氨酸、281位半胱氨酸替换为酪氨酸,通过改变以上一个或多个氨基酸而产生突变扩环酶,并且酶活性有所提高,但酶活性提高依然有限,不能满足工业需求。
目前已经报道,还没有获得针对PenG高活性扩环酶,不能应用到工业生产中。因此,有必要在天然扩环酶序列基础上,设计新颖的G-7-ADCA合成酶,实现PenG到G-7-ADCA的高效生物转化。
发明内容
本发明通过计算机辅助设计获得一系列具有扩环活性的新型G-7-ADCA合成酶(突变体),并通过实验验证,获得提高了对PenG催化活性的G-7-ADCA合成酶。
因而,本发明提供了SEQ ID No.2至SEQ ID No.21所示序列的G-7-ADCA合成酶,还提供了在SEQ ID No.11的基础上发生了C155Y/Y184H、V275I/C281Y/L305M、C155Y/Y184H/V275I/C281Y/L305M、C155Y/Y184H、V275I/C281Y/I305M、或C155Y/Y184H/V275I/C281Y/I305M的突变的G-7-ADCA合成酶;
或者在SEQ ID No.19的基础上发生了C155Y/Y184H、V275I/C281Y/I305M、C155Y/Y184H/V275I/C281Y/I305M的突变的G-7-ADCA合成酶。
进而本发明也提供编码上述G-7-ADCA合成酶的核酸分子。所述核酸分子可以是DNA,如cDNA、基因组DNA或重组DNA;所述核酸分子也可以是RNA,如mRNA、hnRNA或tRNA等。更优选地,所述核酸分子具体为编码上述G-7-ADCA合成酶的基因。
更进一步,本发明提供含上述核酸分子的重组载体、表达盒、转基因细胞系或重组菌也属于本发明的保护范围。所述重组载体可为重组表达载体,也可为重组克隆载体。
本发明还提供所述G-7-ADCA合成酶在催化PenG扩环生成G-7-ADCA提高PenG转化率中的应用。
本发明还一种制备G-7-ADCA的方法,具体包括如下步骤:所述G-7-ADCA合成酶催化PenG进行扩环反应,生成G-7-ADCA。任选地,在所述反应还包括制备所述G-7-ADCA合成酶的步骤,优选地通过重组表达的方式制备所述G-7-ADCA合成酶。可以将PenG与本发明的G-7-ADCA合成酶及其突变体相接触来产生G-7-ADCA,其中G-7-ADCA合成酶及其突变体可以培养液的形式或组合物(其中含有纯化的游离酶、酶的固定化、新型G-7-ADCA合成酶全细胞、全细胞的固定化)的形式使用。优选地,G-7-ADCA合成酶与PenG之间的接触反应可以在溶液中进行。所述催化反应还包括Fe2+和α-酮戊二酸。
优选的,反应体系中PenG的浓度为1-500mM,加入G-7-ADCA合成酶的量为0.1-100U/mL,反应混合液在pH 6到8之间,反应时间0.1至24h,反应温度4至40℃,可以通过常规方法将以上制备的G-7-ADCA从反应混合物中分离和纯化出来。
此外,可以在体内将本发明G-7-ADCA合成酶与PenG相接触,以产生G-7-ADCA。具体而言,可以通过以下步骤产生G-7-ADCA,将所述G-7-ADCA合成酶编码基因或者其功能等效的衍生物导入具有所述G-7-ADCA合成酶活性的微生物(如大肠杆菌,枯草芽孢杆菌,酵母)中;在恰当的条件下,合适的培养基中培养转化体,自发地通过G-7-ADCA合成酶在所述转化体中生物合成G-7-ADCA。
本发明也提供一种用于生产G-7-ADCA的固定化细胞,通过下述方式获得:将发酵的含有所述核酸分子的重组细胞进行收集离心,重悬菌体使其OD600为10到150,添加2-8%的硅藻土,添加0.1-2%w/v絮凝剂,添加0.07-2%v/v交联剂,交联2-3h,获得固定化细胞。
本发明提供的G-7-ADCA合成酶对于底物例如PenG具有比野生型扩环酶高出多倍的扩环活性,具体较大的应用价值。
附图说明
图1全酶法制备G-7-ADCA反应流程图。
图2为计算机设计技术用到的序列比对信息。
图3利用计算模拟技术产生序列酶活信息。
图4G-7-ADCA和PenG液相检测图谱。
具体实施方式
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1:基于数据挖掘技术产生新酶
1.基因获得以及载体构建
以scDAOCS序列为模板,使用BLAST工具通过序列比对,从(National Center forBiotechnology Information,NCBI)数据库中挖掘潜在序列,根据不同的物种来源以及序列相似性(50%-85%),共选取23条序列(表1),并将23条序列进行多序列比对,保留序列最保守的氨基酸,基于此产生一条共有序列(E632,SEQ ID No.2)。经过密码子优化后,利用全基因合成的方式获得全长基因,并将其构建到pET-24a表达载体上。
表1.利用BLAST工具挖掘的23条序列
2.共有序列E632基因表达
将含有E632基因序列的pET-24a表达载体转化大肠杆菌BL21(DE3)中,菌液均匀的涂布在含有50μg/mL卡那霉素抗性的LB平板上,37℃恒温条件下培养14h后长出单菌落,即为含有E632基因工程菌株。同时设置阴性对照组(pET-24a的空载体)。挑取上述单菌落,接种到含有50μg/mL卡那霉素的5mL LB培养基中,37℃、220rpm培养8h;按照1%的接种量转接到含有50μg/mL卡那霉素的100mLTB培养基中,在37℃下培养至OD600=0.6时,加入0.1mMIPTG诱导16h,获得表达E632酶的重组菌体。
3.E632酶催化合成G-7-ADCA
收集上述菌体到50mL离心管,8000rpm离心10min,弃上清,获取菌体,称取湿菌重;添加磷酸盐缓冲液(50mM pH 7.4)至菌浓度为0.1g/mL。取1mL上述菌体重悬液分别添加5mMPenG、6mMα-酮戊二酸、0.4mM抗坏血酸、50μg/mL FeSO4,30℃反应2h。添加1mL甲醇终止反应,1200rpm离心3min,取上清进行液相色谱(HPLC)检测G-7-ADCA的含量。
HPLC检测条件为:
色谱柱:Agilent ZORBAX SB-C18 Stable Bond Analytical 4.6×250mm;流动相:20mM pH 3.0磷酸钠缓冲液:甲醇=55:45;流速:1mL/min;检测波长215nm。
所用标准品为G-7-ADCA(山东鲁抗药业股份有限公司),利用G-7-ADCA制备标准曲线。液相检测结束后根据标准曲线计算摩尔转化率,转化率(%)=100×P/(5×10-3),P为液相检测出G-7-ADCA的摩尔浓度(mol/L)。
表2共有序列E632的催化效率
由表2可知,E632酶对底物PenG具有催化活性。
实施例2:基于结构片段重组技术产生新酶
1.新酶基因获得以及载体构建
利用结构片段重组技术,获得19条G-7-ADCA合成酶序列(编号为从E719至E737)。经过密码子优化后,利用全基因合成的方式获得全长基因,并将其构建到pET-24a表达载体上。
具体过程如下:利用结构片段重组技术,大量产生自然界酶家族中的二级结构片段,并快速重组成全新的嵌合酶,通过打分函数评估3条扩环酶亲本序列中哪些片段可以进行互换,而不对蛋白的整体结构产生严重破坏作用,3条亲本序列的比对如图2所示,其中包括实施例1中所产生的共有序列E632,SEQ ID No.2。利用重组最短路径问题(Recombination as Shortest Path Problem,RASPP)算法共识别出4个最优计算模拟文库,将3条亲本序列分别截断为6、7、8、9个砌块(blocks),统一根据平均<E>值,选择出序列截断位置集,最后通过视觉观察scDAOCS的三维晶体结构(PDB:1UOB),最终选择出的交叉位点为[50,126,150,184,237],[50,73,118,150,188,242],[37,50,70,106,179,268,299],[37,59,93,118,136,166,188,237],4个计算模拟文库分别包括36(729),37(2187),38(6561),39(19683)条重组序列,共29160条序列。由于不可能对所有的重组序列进行合成及表征,所以统一根据平均扰动<E>值及最大突变数<m>值为原则,目的是增加选取序列的多样性,与野生型序列相比,序列相似性降为70%,每个文库分别选取5条进行合成及表征,总共选取了19条序列。经过密码子优化后,利用全基因合成的方式获得全长基因,并将其构建到pET-24a表达载体上。
2.新酶基因表达
按照实施例1方法对上述19条序列的新酶(编号为从E719至E737)基因进行表达。
3.新酶全细胞催化合成G-7-ADCA
按照实施例1方法对上述19个新酶进行催化合成G-7-ADCA。新酶酶活(图3)以及催化PenG合成G-7-ADCA转化率如表3。
1个酶活力性单位(U):30℃,1min产生1mM的G-7-ADCA。
比酶活(U/mL):每毫升酶蛋白所具有的酶活力。
表3利用重组技术产生的新型合成酶催化效率
根据表3和图3,19条序列新酶均对底物PenG具有活性,相对于E632而言,活性都得到提高,而以E727及E735酶活性最高。
实施例3:E727以及E735粗酶液催化合成G-7-ADCA
将实施例2中含有E727和E753基因序列的pET24a质粒(pET24a-E727和pET24a-E735)分别转化到大肠杆菌BL21(DE3),将转化后的大肠杆菌BL21(DE3)菌液均匀的涂布在含有50μg/mL卡那霉素抗性的LB平板上,37℃培养14h后长出单菌落,即为含有E727和E735基因的工程菌株。挑取上述单菌落,接到含有50μg/mL卡那霉素的5mL LB培养基中,37℃培养6h,按1%的接种量接种在含有50μg/mL卡那霉素的200mLTB培养基中,37℃培养3h,添加1mM IPTG 25℃诱导13h。收集菌体,称取湿菌重,添加磷酸缓冲液使菌终浓度为0.25g/mL(每毫升含有湿菌体的重量),对菌体进行超声破碎,破碎后裂解液12000rpm离心30min,收集上清液。对上清液进行如下反应:
取1mL上清液(粗酶液)分别添加20mMPenG、30mMα-酮戊二酸、0.4mM抗坏血酸、50μg/mL FeSO4,30℃反应2h。添加1mL甲醇终止反应,按照实施例1方法对反应后的样品进行G-7-ADCA和PenG含量的检测,并计算转化率。检测结果见表4,2h转化率达60%以上。
表4 E727和E735粗酶液转化率
实施例4:E727以及E735全细胞催化合成G-7-ADCA
按照实施例3的方式培养菌体,收集菌体,用磷酸缓冲液溶解菌体,调整菌体的OD600为50,取100mL上述菌体,分别添加30mMPenG、45mMα-酮戊二酸、0.4mM抗坏血酸、0.5μg/mL,FeSO430℃反应2h,取1mL上述反应液,12000rpm离心3min,取上清50μL,添加950μL甲醇。按照实施例1方法对反应后的样品进行G-7-ADCA和PenG含量的检测。检测结果见表5。
表5 E727和E735全细胞转化率
实施例5:固定化E727以及E735的全细胞催化合成G-7-ADCA
按照实施3培养菌体,收集菌体,调整OD600=100,向悬液中添加1%硅藻土,搅拌均匀,随后添加0.5%w/v分子量为10000的聚乙烯亚胺,水溶液在室温下絮凝,然后添加2%v/v戊二醛水溶液下交联2h,获得固定化的细胞。在100ml的反应体系下,分别加入终浓度OD600=50菌液、30mMPenG、45mMα-酮戊二酸、0.4mM抗坏血酸、50μg/mL FeSO4,补加pH7.4磷酸盐缓冲液到100mL,30℃反应2h,按照实施例1方法对反应后的样品进行G-7-ADCA和PenG含量的检测,固定化E727以及E735的全细胞转化率分别为79%和80%。
实施例6:对E727以及E735酶进行理性改造
1、E727以及E735理性改造
为了获得针对底物PenG活性更高的扩环酶,对E727及E735进行理性改造。将E727和E735分别与SEQ ID No.1序列进行比对。构建如下突变体:E727M2(C155Y/Y184H)、E727M3(V275I/C281Y/L305M)、E727M5(C155Y/Y184H/V275I/C281Y/L305M)、E735M2(C155Y/Y184H)、E735M3(V275I/C281Y/I305M)、E727M5(C155Y/Y184H/V275I/C281Y/I305M)。
2、构建E727以及E735突变体载体
为了构建E727以及E735突变体载体,设计引物见表6:
表6引物列表
(1)构建E727M2(C155Y/Y184H)突变体载体
以质粒pET24a-E727为模板,分别取727M2-F和727M2-R引物对扩增获得片段P1(155-184片段)、以片段P1作为大引物,用KOD-plus DNA聚合酶做MegaPrimer PCR。
第一轮PCR反应体系(50μL)包括:10ng质粒模板,10pmol的引物对,1xKOD plusbuffer,0.2mMdNTP,1.5mM MgSO4,5个单位的KOD-plus DNA聚合酶。
第一轮PCR反应条件为:95℃2min;98℃10s,57℃30s,68℃1min/kbp;30个循环;68℃10min。胶回收片段P1。
第二轮PCR以片段P1作为大引物,用KOD-plus DNA聚合酶做MegaPrimer PCR。
MegaPrimer PCR反应体系(50μL)包括:10ng质粒模板,250ng片段P1,1xKOD plusbuffer,0.2mMdNTP,1.5mM MgSO4,5个单位的KOD-plus DNA聚合酶。
MegaPrimer PCR反应条件为:94℃5min;98℃10s,60℃30s,68℃2min/kbp,25个循环;68℃10min。DpnI消化质粒模板,电转化大肠杆菌BL21(DE3),挑取单菌落测序鉴定。经测序获得含有C155Y/Y184H突变位点的pET24a-E727M2(C155Y/Y184H)表达载体。
(2)构建E727M3(V275I/C281Y/L305M)突变体载体
以质粒pET24a-E727为模板,分别取727M3-F和727M3-R引物对扩增获得片段P2(275-305片段)、以片段P2作为大引物,用KOD-plus DNA聚合酶做MegaPrimer PCR,获得含有V275I/C281Y/L305M突变位点的pET24a-E727M3(V275I/C281Y/L305M)表达载体。PCR反应体系和反应条件同上。
(3)构建E727M5(C155Y/Y184H/V275I/C281Y/L305M)突变体载体
以质粒pET24a-E727M2(C155Y/Y184H)为模板,分别取727M3-F和727M3-R引物对扩增获得片段P3(155-305片段)、以片段P3作为大引物,用KOD-plus DNA聚合酶做MegaPrimer PCR,获得含有C155Y/Y184H/V275I/C281Y/L305M突变位点的pET24a-E727M3(C155Y/Y184H/V275I/C281Y/L305M)表达载体。PCR反应体系和反应条件同上。
突变体E735M2(C155Y/Y184H)、E735M3(V275I/C281Y/I305M)、E727M5(C155Y/Y184H/V275I/C281Y/I305M)载体的构建方法同上,经测序鉴定,获得了pET24a-E735M2(C155Y/Y184H)、pET24a-E735M3(V275I/C281Y/I305M)以及pET24a-E727M5(C155Y/Y184H/V275I/C281Y/I305M)表达载体。
3、E727和E735突变体基因表达及催化合成G-7-ADCA
按照实施例1的方式表达E727以及E735突变体的基因。
按照实施例1的方式检测E727以及E735突变体催化合成G-7-ADCA。
表7理性改造E727以及E735突变体转化率
由表7可知,与对照E727和E735比较,突变体转化率有不同程度的提高,其中E727M2催化PenG合成G-7-ADCA的转化率最高。
实施例6:E727M2粗酶液催化合成G-7-ADCA
将含有E727M2基因序列的pET24a质粒(pET24a-E727M2)转化到大肠杆菌BL21(DE3),按照实施例3方法获得粗酶液。对粗酶液进行酶活性验证,在1mL粗酶液中分别添加20mM PenG、30mMα-酮戊二酸、0.4mM抗坏血酸、50μg/mL FeSO4,30℃反应2h。添加1mL甲醇终止反应,12000rpm离心3min。按照实施例1方法对反应后的样品进行G-7-ADCA和PenG检测,并计算转化率。按照实施例1方法对反应后的样品进行G-7-ADCA和PenG检测,2h转化率达95%。
实施例7:E727M2全细胞催化合成G-7-ADCA
按照实施例3的方式培养菌体,收集菌体,用磷酸缓冲液溶解菌体,调整菌体的OD600为50,取100mL上述菌体,分别添加30mM PenG、45mMα-酮戊二酸、0.4mM抗坏血酸、0.5μg/mLFeSO4,30℃反应2h。取1mL上述反应液,12000rpm离心3min,取上清50μL,添加950μL甲醇。按照实施例1方法对反应后的样品进行G-7-ADCA和PenG检测。2h转化率达90%。
实施例8:固定化E727M2全细胞催化合成G-7-ADCA
按照实施例5培养菌体,收集菌体,调整OD600=100,向悬液中添加1%硅藻土,搅拌均匀,随后添加0.5%w/v分子量为10000的聚乙烯亚胺,水溶液在室温下絮凝,然后添加2%v/v戊二醛水溶液下交联2h,获得固定化的细胞,在100mL的反应体系下,分别加入终浓度OD=50,分别添加30mM PenG、45mMα-酮戊二酸、0.4mM抗坏血酸、0.5μg/mLFeSO4,30℃反应2h,补加pH7.4磷酸盐缓冲液到100ml,30℃反应2h,通过HPLC检测转化率可达90%。
<110> 中国科学院天津工业生物技术研究所
<120> G-7-ADCA合成酶及其在制备头孢烷酸类化合物中的应用
<160> 21
<210> 1
<211> 311
<212> PRT
<213> 人工序列
<400> 1
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTQYFDRQYTASRAVAREVLRATGTEPDGGVEAFLDYEPLLRFRYFPQVPEHRSAEEQPLRMAPHHDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPRHHVAAPRRDQIAGSSRTSSVFFLRPNADFTFSIPLAREYGFDVSLDGETATFQDWIGGNYVNMRRTSKA 311
<210> 2
<211> 311
<212> PRT
<213> 人工序列
<400> 2
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLSEADHKSAKDVAVDFFEHGTEEEKRAVTSPIPTIRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSIVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPRHHVAAPGRDQRAGSSRTSSVFFLRPKSDFSFSVPLARECGFDVSLDGETATFGDWIGGNYVNIRRTSKA 311
<210> 3
<211> 311
<212> PRT
<213> 人工序列
<400> 3
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLAVDFFEHGTEEEKRAVTSPIPTIRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYTASRAVAREVLRATGTEPDGGVEAFLDYEPLLRFRYFPQVPEHRSAEEQPLLMAPHHDLSIVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 4
<211> 311
<212> PRT
<213> 人工序列
<400> 4
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLSEADHKSAKDVAVDFFEHGTEEEKRAVTSPIPTIRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYTASRAVAREVLRATGTEPDGGVEAFLDYEPLLRFRYFPQVPEHRSAEEQPLLMAPHHDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 5
<211> 311
<212> PRT
<213> 人工序列
<400> 5
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTQYFDRQYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPRHHVAAPGRDQRAGSSRTSSVFFLRPKSDFSFSVPLARECGFDVSLDGETATFGDWIGGNYVNIRRTSKA 311
<210> 6
<211> 311
<212> PRT
<213> 人工序列
<400> 6
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLSEADHKSAKDVVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTQYFDRQYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 7
<211> 311
<212> PRT
<213> 人工序列
<400> 7
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDYEPLLRFRYFPQVPEHRSAEEQPLLMAPHHDLSMVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPRHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 8
<211> 311
<212> PRT
<213> 人工序列
<400> 8
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLAVDFFEHGTEEEKRAVTSPIPTIRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDYEPLLRFRYFPQVPEHRSAEEQPLLMAPHHDLSMVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPRHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 9
<211> 311
<212> PRT
<213> 人工序列
<400> 9
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLSEADHKSAKDVAVDFFEHGTEEEKRAVTSPIPTIRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTQYFDRQYTASRAVAREVLRATGTEPDGGVEAFLDYEPLLRFRYFPQVPEHRSAEEQPLLMAPHHDLSMVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPRHHVAAPGRDQRAGSSRTSSVFFLRPKSDFSFSVPLARECGFDVSLDGETATFGDWIGGNYVNIRRTSKA 311
<210> 10
<211> 311
<212> PRT
<213> 人工序列
<400> 10
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLVVDFFEHGTEEEKRAVTSPVPTIRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPTADFERVWTQYFDRQYTASRAVAREVLRATGTEPDGGVEAFLDYEPLLRFRYFPQVPEHRSAEEQPLLMAPHHDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPRHHVAAPGRDQRAGSSRTSSVFFLRPKSDFSFSVPLARECGFDVSLDGETATFGDWIGGNYVNIRRTSKA 311
<210> 11
<211> 311
<212> PRT
<213> 人工序列
<400> 11
MDTTVPTFHLAELQEGLHQDEFRSCLMEKGVFYLTGSSLSEADQKSAKDVVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSIVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPRHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 12
<211> 311
<212> PRT
<213> 人工序列
<400> 12
MDTTVPTFHLAELQEGLHQDEFRSCLMEKGVFYLTGSGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPTADFERVWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSIVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPRHHVAAPGRDQRAGSSRTSSVFFLRPKADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 13
<211> 311
<212> PRT
<213> 人工序列
<400> 13
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTIRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHHDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPRHHVAAPRRDQIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 14
<211> 311
<212> PRT
<213> 人工序列
<400> 14
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTQYFDRQYTASRAVAREVLRATGTEPDGGVEAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSMVTLIQQTPCANGFVSLQAEVGGAFTDLPYRPDAVLVFCGAIATLVTGGQVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNIRRTSKA 311
<210> 15
<211> 311
<212> PRT
<213> 人工序列
<400> 15
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLSEADHKSAKDVAVDFFEHGTEEEKRAVTSPIPTIRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPTADFERVWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSMVTLIQQTPCANGFVSLQAEVGGAFTDLPYRPDAVLVFCGAIATLVTGGQVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNSDFSFSVPLARECGFDVSLDGETATFGDWIGGNYVNMRRTSKA 311
<210> 16
<211> 311
<212> PRT
<213> 人工序列
<400> 16
MDTTVPTFHLAELQEGLHQDEFRSCLMEKGVFYLTGSGLSEADHKSAKDVVVDFFEHGTEEEKRAVTSPVPTIRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPSGDFERIWTQYFDRQYTASRAVAREVLRATGTEPDGGVEAFLDYEPLLRFRYFPQVPEHRSAEEQPLLMAPHYDLSMVTLIQQTPCANGFVSLQAEVGGAFTDLPYRPDAVLVFCGAIATLVTGGQVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSIPLAREYGFDVSLDGETATFQDWIGGNYVNMRRTSKA 311
<210> 17
<211> 311
<212> PRT
<213> 人工序列
<400> 17
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEQPLLMAPHHDLSMVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 18
<211> 311
<212> PRT
<213> 人工序列
<400> 18
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLVIDFFEHGSEEEKRAVTSPIPTIRRGFSGLESESTAQITNTGTYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYDASREVARQVLRATGTEPDGGVEAFLDCEPLLRFRYFPEVPEHRSAEEQPLLMAPHHDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 19
<211> 311
<212> PRT
<213> 人工序列
<400> 19
MDTTVPTFSLAELQQGLHQDEFRRCLRDKGLFYLTDCGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYTDYSMCYSMGTSDNLFPTADFERVWTHYFDRMYDASREVARQVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSMVTLIQQTPCANGFVSLQAEVDGTFVDLPARPDAVLVFCGAVATLVTGGKVKAPKHHVVAPARDRIAGSSRTSSVFFLRPNADFTFSVPLAKRCGFDIGLDGDTAAFQDWIAGNYVNLRTKTKA 311
<210> 20
<211> 311
<212> PRT
<213> 人工序列
<400> 20
MDTTVPTFSLDELQEGLHQDEFRRCLTEKGVFYLTDSGLTDTELKSAKDLVIDFFEHGSEEEKRAVTSPVPTIRRGFTGLESESTAQITNTGSYTDYSMCYSMGTSDNLFPTADFERVWTQYFDRQYTASRAVAREVLKATGTEPDGGVDAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSMVTLIQQTPCANGFVSLQAEVGGAFTDLPYRPDAVLVFCGAIATLVTGGQVKAPRHHVAAPRRDQIAGSSRTSSVFFLRPNADFTFSIPLAREYGFDVSLDGETATFQDWIGGNYVNMRRTSKA 311
<210> 21
<211> 311
<212> PRT
<213> 人工序列
<400> 21
MDTTVPTFHLAELQEGLHQDEFRSCLMEKGVFYLTGSGLTDTELKSAKDLVIDFFEHGSEAEKRAVTSPVPTTRRGFTGLESESTAQITNTGSYSDYSMCYSMGTADNLFPSGDFERIWTQYFDRQYTASRAVAREVLRATGTEPDGGVEAFLDCEPLLRFRYFPEVPEHRSAEEEPLRMAPHYDLSMVTLIQQTPCANGFVSLQAEVGGAFVDLPYRPDAVLVFCGAIATLVTGGQVKAPRHHVAAPGRDQRAGSSRTSSVFFLRPKSDFSFSVPLARECGFDVSLDGETATFGDWIGGNYVNIRRTSKA 311
Claims (10)
1.一种G-7-ADCA合成酶,其特征在于,氨基酸序列如SEQ ID No. 2至SEQ ID No. 21任一所示,或者
在SEQ ID No.11的基础上发生了C155Y/Y184H、V275I/C281Y/L305M、C155Y/Y184H/V275I/C281Y/L305M、C155Y/Y184H、V275I/C281Y/I305M、或C155Y/Y184H/V275I/C281Y/I305M的突变;
或者在SEQ ID No.19的基础上发生了C155Y/Y184H、V275I/C281Y/I305M、C155Y/Y184H/V275I/C281Y/I305M的突变。
2.编码如权利要求1所述的G-7-ADCA合成酶的核酸分子;具体地,所述核酸分子是DNA,如cDNA、基因组DNA或重组DNA;或者是RNA,如mRNA、hnRNA或tRNA;更优选地,所述核酸分子具体为编码上述G-7-ADCA合成酶的基因。
3.含有如权利要求2所述的核酸分子的重组载体、表达盒、转基因细胞系或重组菌;所述重组载体为重组表达载体或重组克隆载体;优选将转基因细胞系固定化得到固定化细胞。
4.一种用于生产G-7-ADCA的固定化细胞,通过下述方式获得:将发酵的含有如权利要求2所述核酸分子的重组细胞进行收集离心,重悬菌体使其OD600为10到150,添加2-8%的硅藻土,添加0.1-2% w/v絮凝剂,添加0.07-2% v/v交联剂,交联2-3 h,获得固定化细胞。
5.如权利要求1所述的G-7-ADCA合成酶在催化PenG扩环生成G-7-ADCA中的应用。
6.一种制备G-7-ADCA的方法,具体包括如下步骤:将如权利要求1所述的G-7-ADCA合成酶催化PenG进行扩环反应,生成G-7-ADCA;任选地,所述反应还包括制备所述G-7-ADCA合成酶的步骤,优选地通过重组表达的方式制备所述G-7-ADCA合成酶。
7.如权利要求6所述的方法,其特征在于,还包括对制备得到的G-7-ADCA从反应的混合物中进行分离和纯化。
8.如权利要求6所述的方法,其特征在于,将PenG与所述的G-7-ADCA合成酶相接触来产生G-7-ADCA。
9.如权利要求8所述的方法,其特征在于,所述的G-7-ADCA合成酶以培养液的形式或组合物的形式使用,例如以含有纯化的游离酶、酶的固定化、全细胞、全细胞的固定化的形式使用;优选地,G-7-ADCA合成酶与PenG之间的接触反应可以在溶液中进行;
优选的,在反应体系中PenG的浓度为1-500 mM,加入G-7-ADCA合成酶的量为0.1-100U/mL,反应混合液在pH 6到8之间,反应时间0.1至24 h,反应温度4至40℃;进一步的所述催化反应还包括Fe2+和α-酮戊二酸。
10.如权利要求8所述的方法,其特征在于,在细胞体内实现G-7-ADCA合成酶与PenG相接触,以催化产生G-7-ADCA;具体地,通过以下步骤产生G-7-ADCA,将导入有所述G-7-ADCA合成酶编码基因的重组微生物(如细菌,具体如大肠杆菌,枯草芽孢杆菌;如真菌,具体如酵母)进行培养,在培养基中添加底物PenG,通过生物合成G-7-ADCA。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210061179.6A CN116497010A (zh) | 2022-01-19 | 2022-01-19 | G-7-adca合成酶及其在制备头孢烷酸类化合物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210061179.6A CN116497010A (zh) | 2022-01-19 | 2022-01-19 | G-7-adca合成酶及其在制备头孢烷酸类化合物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116497010A true CN116497010A (zh) | 2023-07-28 |
Family
ID=87318886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210061179.6A Pending CN116497010A (zh) | 2022-01-19 | 2022-01-19 | G-7-adca合成酶及其在制备头孢烷酸类化合物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116497010A (zh) |
-
2022
- 2022-01-19 CN CN202210061179.6A patent/CN116497010A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3072101B2 (ja) | 7―adcaの生化学的新規製造法 | |
CN103937764B (zh) | 头孢菌素类抗生素原料物质(7‑aca)生产用变异酶 | |
JP4108766B2 (ja) | 改良されたトランスアミナーゼ生物学的変換方法 | |
WO2017143944A1 (zh) | 一种青霉素g酰化酶突变体 | |
Yang et al. | Expression and purification of extracellular penicillin G acylase in Bacillus subtilis | |
Sambyal et al. | Exploitation of E. coli for the production of penicillin G amidase: a tool for the synthesis of semisynthetic β-lactam antibiotics | |
WO2018165881A1 (zh) | 一种头孢菌素c酰化酶突变体及其应用 | |
KR100244066B1 (ko) | D-N-카르바모일-α-아미노산의 제조법 | |
Luo et al. | Gene cloning, overexpression, and characterization of the nitrilase from Rhodococcus rhodochrous tg1-A6 in E. coli | |
Wang et al. | Double knockout of β-lactamase and cephalosporin acetyl esterase genes from Escherichia coli reduces cephalosporin C decomposition | |
CN116497010A (zh) | G-7-adca合成酶及其在制备头孢烷酸类化合物中的应用 | |
CN107304418B (zh) | 青霉素扩环酶突变体、编码该突变体的dna、含有该突变体的试剂盒及其应用 | |
US11760988B2 (en) | L-aspartate alpha-decarboxylase mutant and application thereof | |
CN106399174A (zh) | 一株青霉素酰化酶及其编码基因、产生菌和应用 | |
US9404139B2 (en) | Mutated cephalosporin hydroxylase and its application in deacetylcephalosporanic acid synthesis | |
Luo et al. | Cloning and co-expression of D-amino acid oxidase and glutaryl-7-aminocephalosporanic acid acylase genes in Escherichia coli | |
WO2007073947A2 (en) | Mutant type ii beta- lactam acylases | |
CN116478940A (zh) | 扩环酶突变体及其在合成g-7-adca中的应用 | |
CN112852912B (zh) | 一种合成7-氨基去乙酰氧基头孢烷酸的方法 | |
CN115786296B (zh) | 一种内消旋-二氨基庚二酸脱氢酶突变体及生产方法 | |
CN117247928A (zh) | 一种头孢菌素c酰化酶催化的酰化反应及其应用 | |
CN114686500B (zh) | 一种1,4-α-葡聚糖分支酶、编码基因及工程菌株与应用 | |
JP4513967B2 (ja) | D−アミノアシラーゼの活性向上方法 | |
Wen et al. | Expression, purification, and characterization of His-tagged penicillin G acylase from Kluyvera citrophila in Escherichia coli | |
CN117247925A (zh) | 头孢菌素c酰化酶突变体及其在头孢菌素母核合成中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |